Outrun Therapeutics
Drug Discovery
- Website
- https://outruntx.com/
- Membership category
- Corporate
Errol Road, Invergowrie, Dundee, DD2 5DA, United Kingdom
Outrun Therapeutics at a glance
Outrun Therapeutics is developing small molecule inhibitors of E3 Ligases to stabilize proteins and treat cancer.
About Outrun Therapeutics
Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 ligase inhibition to maintain levels of critical proteins that are otherwise destabilised in certain diseases, disrupting the body’s highly sophisticated natural disease suppression processes. Despite the very high interest in E3 ligases as a therapeutic target, they have been challenging to drug. This is a roadblock that Outrun is addressing through its world class knowledge of E3 ligase biology and its proprietary discovery platform. Outrun’s proprietary XE3L platform has enabled Outrun to build a pipeline of highly valuable small molecule first-in-class, E3 ligase inhibitors to prevent protein degradation. Outrun’s lead programme is a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours. Spun out of founder Prof. Satpal Virdee’s lab at the University of Dundee, Outrun is led by a seasoned management team with a strong track record in creating robust biopharma businesses and is backed by M Ventures and MP Healthcare Venture Management.
